Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Diacetyldianhydrogalactitol** is an acetylated derivative of dianhydrogalactitol (DAG), sometimes referred to as dianhydro-3,4-diacetylgalactitol or 3,4-di-O-acetyl-1,2:5,6-dianhydrogalactitol[2][4]. The compound is a small molecule with a chemical formula C10H14O6 and a molecular weight of 230.22 g/mol[2]. It is structurally related to dianhydrogalactitol, a DNA-alkylating agent with antineoplastic activity. Diacetyldianhydrogalactitol and related analogs may act as bifunctional alkylators, forming DNA cross-links via the diepoxide motif after metabolic activation, leading to disruption of DNA function and cell cycle arrest[4]. Diacetyldianhydrogalactitol is considered a chemical derivative/prodrug of dianhydrogalactitol and may possess similar cytotoxic and antitumor properties, although specific pharmacology and clinical testing status for diacetyldianhydrogalactitol are less well characterized in the literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diacetyldianhydrogalactitol.